Entering text into the input field will update the search result below

Vascepa Script Numbers Continue To Build Nicely

Jun. 28, 2013 5:10 PM ETAMRN, GSK21 Comments
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Vascepa refills up over 12%, double digit base growth too. On track to meet or exceed FY analyst revenue estimates.

Lovaza and Niacin share directly going to Vascepa.

GSK has to be talking to AMRN at this point.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You